Abstract
Hydrazine sulfate is used industrially in metal refining, and in analytical tests for blood. It is used as an antioxidant agent in soldering flux and as a fungicide, although it is not registered as such in the United States (National Safety Council, 2000). Other chemicals in the hydrazine class include the antituberculosis drug isoniazid and the cancer chemotherapy drug procarbazine. Over 400 hydrazine compounds have been studied over the past century, and 7 have been identified as having anticancer activity in human tumors. One of these, methylhydrazine, showed activity in patients with Hodgkin’ s disease, melanoma, and lung cancer in the 1960s. Hydrazine sulfate was subsequently investigated because of its structural similarity to methylhydrazine (National Cancer Institute, 2000). In the early 1970s, hydrazine sulfate was studied in humans as a treatment for cancer by Dr. Joseph Gold of the Syracuse Cancer Research Institute (Gold, 1975). Russian investigators also began studying hydrazine sulfate at this time. Although tumor response was poor, nutritional status was thought to benefit (National Cancer Institute, 2000).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anonymous. Hydrazine sulfate. Available from: URL: . http://www.ndcrt.org/data/Accessed July 13, 2000.
Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate influence on nutritional status and survival in non-small cell lung cancer. J Clin Oncol 1990; 8: 9–15.
Colvin LB. Metabolic fate of hydrazine and hydrazides. J Pharm Sci 1969; 58: 1433–43.
Dabney, BJ. Hydrazine (REPROTEXT® Document). In: Heitland G, and Hurlbut KM (Eds.): REPROTEXT® Database. MICROMEDEX, Greenwood Village, Colorado (Edition expires 12/2002).
Donald PR, Seifart HI, Parkin DP, van Jaarsveld PP. Hydrazine production in children receiving isoniazid for the treatment of tuberculosis meningitis. Ann Pharmacother 1994; 28: 1340–3.
Gent WL, Seifart HI, Parkin DP, Donald PR, Lamprecht JH. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. Eur J Clin Pharmacol 1992; 43: 131–6.
Gold J. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. Oncology 1975; 32: 1–10.
Gold J. Incompatibility of hydrazine sulfate and pentobarbital in the treatment of tumor bearing animals [abstract]. Proc Am Assoc Cancer Res 1977; 8: 250.
Gold J. Hydrazine sulfate: a current perspective. Nutr Cancer 1987; 9: 59–66.
Gold J. More about: the biology of cachexia [letter]. J Natl Cancer Inst 1998; 90: 1101–2.
Hainer MI, Tsai N, Komura ST, Chiu CL. Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000; 133: 877–80.
Hansten P, Horn J. Drug interactions analysis and management. St. Louis, MO: Facts and Comparisons, 1999.
Harati Y, Niakan E. Hydrazine toxicity, pyridoxine therapy, and peripheral neuropathy [letter]. Ann Intern Med 1986; 104: 728–9.
Jenner AM, Timbrell JA. Influence of inducers and inhibitors of cytochrome P450 on the hepatotoxicity of hydrazine in vivo. Arch Toxicol 1994; 68: 349–57.
Jia F, Morrison D, Silverstein R. Hydrazine sulfate selectivity modulates the tumor necrosis factor response to endotoxin in mouse macrophages. Circ Shock 1994; 42: 111–114.
Kaegi E. Unconventional therapies for cancer. CMAJ 1998; 158: 1327–30.
Kamradt J, Pienta K. The effect of hydrazine sulfate on prostate cancer. Oncol Rep 1998; 5: 919–21.
Kaneo Y, Iguchi S, Kubo H, et al. Tissue distribution of hydrazine and its metabolites in rats. J Pharmacobiodyn 1984; 7: 556–67.
Kosty MP, Fleishman SB, Herndon JE, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994; 12: 1113–20.
Life Energy Distributor. Personal communication, Dr. Benjamin. PO Box 550, Abbotsford, B.C. V2S 5Z5, Canada. Tel: 1–604–856–0170.
Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994a; 12: 1126–9.
Loprinzi CL, Kuross SA, O’Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994b; 12: 1121–5.
Malozowski S. Hydrazine sulfate. Available from: URL: http://www.fda.gov/cder/pharmcomp/meeting/hydraz.ppt. Accessed August 2, 2001.
Michaelis K. News. Available from: URL: http://www.holisticalternatives.net/News.htm. Accessed August 2, 2001.
Michelot D, Toth B. Poisoning by Gyromita esculenta—a review. J Appl Toxicol 1991; 11: 235–43.
National Cancer Institute. Hydrazine sulfate. Available from: URL: http://www.cancer.gov/cancer_information. Accessed February 18, 2002.
Nagapappan R, Ridell T. Pyridoxine therapy in a patient with severe hydrazine sulfate toxicity. Crit Care Med 2000; 28: 2116–8.
National Safety Council. Environmental Health Center. Environment writer. Hydrazine (N2H4) and hydrazine sulfate (H4N2.H2O4S) chemical backgrounder. Available from: URL: http://www.nsc.org/ehc/ew/chems/hydrazine.htm. Accessed July 20, 2000.
Preece NE, Forrow S, Ghatineh S, Langley GJ, Timbrell JA. Determination of hydrazine in biofluids by capillary gas chromatography with nitrogen-sensitive or mass spectrometric detection. J Chromatogr 1992a; 573: 227–34.
Preece N, Ghatineh S, Timbrell J. Studies on the disposition and metabolism of hydrazine in rats in vivo. Hum Exp Toxicol 1992b; 11: 121–7.
Ravindranath T, Topaloglu AK, Goto M, Zeller WP. Effects of hydrazine sulfate on galactosaminesensitized endotoxic shock in ten-day-old rats. Res Commun Mol Pathology 1998; 99: 233–9.
Runge-Morris M, Feng Y, Zangar RC, Noval RF. Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic and renal drug-matabolizing enzyme expression. Drug Metab Dispos 1996; 24: 734–7.
Runge-Morris M, Wu N, Novak RF. Hydrazine-mediated DNA damage: role of hemoprotein, electron transport, and organic free radivcals. Toxicol Appl Pharmacol 1994; 125: 123–32.
Sarich TC, Youssefi M, Zhou T, et al. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch Toxicol 1996; 70: 835–40.
Seifart HI, Gent WL, Parkin DP, van Jaarsveld PP, Donald PR. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr B Biomed Appl 1995; 674: 269–275.
Seits IF, Gershanovich ML, Filov VA, et al. Experimental and clinical data on antitumor action of hydrazine sulphate [Russian]. Vopr Onkol 1975; 21: 45–52.
Tretyakov AV, Filov VA. Concerning the mechanism of the enhancement of antitumor drugs effect by hydrazine sulphate. Vopr Onkol 1977; 23: 94–8.
Walubo A, Chan K, Wong C. The pharmacokinetics of isoniazid and hydrazine metabolite in plasma and cerebrospinal fluid of rabbits. Methods Find Exp Clin Pharmacol 1991; 13: 199–204.
Woodward KN, Timbrell JA. Acetylhydrazine hepatotoxicity: the role of covalent binding. Toxicology 1984; 30: 65–74.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dingess, O., Cupp, M.J., Tracy, T.S. (2003). Hydrazine Sulfate. In: Cupp, M.J., Tracy, T.S. (eds) Dietary Supplements. Forensic Science and Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-303-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-59259-303-3_15
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9726-7
Online ISBN: 978-1-59259-303-3
eBook Packages: Springer Book Archive